$PRXL (PAREXEL International Corporation)

$PRXL {{ '2016-01-19T18:02:19+0000' | timeago}} • Announcement

Biopharmaceutical services company $PRXL said that it has agreed to acquire all outstanding equity securities of Health Advances, LLC, a life sciences consulting firm. The acquisition is expected to close in Feb., subject to closing conditions including expiration or termination of waiting period under the Hart-Scott-Rodino Act.

$PRXL {{ '2017-09-29T18:06:28+0000' | timeago}} • Announcement

Investment management firm Pamplona Capital Management has completed the acquisition of $PRXL, a bio-pharmaceutical services firm, for $88.10 per share in cash. Pursuant to the buyout, PAREXEL stock will stop trading on the Nasdaq Stock Exchange from September 29, 2017. Josef von Rickenbach will continue as CEO of the acquired entity.

$PRXL {{ '2017-09-18T13:38:17+0000' | timeago}} • Announcement

$PRXL shareholders have approved the proposed acquisition of the company by certain investment funds affiliated with Pamplona Capital Management. Under the terms of the acquisition, Pamplona will acquire all outstanding shares of PAREXEL for $88.10 per share in cash. The closing of the transaction is anticipated on or about Sept 29, 2017.

$PRXL {{ '2017-08-28T22:48:19+0000' | timeago}} • Announcement

For 4Q17, $PRXL’s service revenue increased 3.8% to $557.2MM compared with 4Q16. On a segment basis, service revenue was $432.3MM in Clinical Research Services, $50MM in PAREXEL Consulting and $74.9MM in PAREXEL Informatics.

$PRXL {{ '2017-08-28T22:44:05+0000' | timeago}} • Announcement

$PRXL reported a decrease in 4Q17 earnings. Net income was $29.9MM or $0.58 per share compared to $42.7MM or $0.80 per share in 4Q16. Adjusted net income was $52.2MM or $1.02 per share in 4Q17. Total revenues grew to $647.6MM from $625.5MM last year.

$PRXL {{ '2017-08-21T17:19:23+0000' | timeago}} • Announcement

$PRXL, a biopharma service provider, and Osaka International Cancer Institute have joined hands to advance clinical development in Japan. The venture aims to drive greater efficiencies in patient recruitment for clinical trials in oncology and hematology and accelerate the development of innovative and effective new cancer treatments for patients.

$PRXL {{ '2017-06-20T12:22:29+0000' | timeago}} • Announcement

$PRXL agreed to be acquired by Pamplona Capital Management, LLP. Bank of America Merrill Lynch and J.P. Morgan Chase Bank, N.A. have provided committed financing for the transaction. Upon the completion of the transaction, $PRXL will become a privately held company and shares of $PRXL's common stock will no longer be listed on any public market.

$PRXL {{ '2017-06-20T12:21:26+0000' | timeago}} • Announcement

$PRXL agreed to be acquired by Pamplona Capital Management, LLP for $88.10 per share in cash in a transaction valued at about $5Bil, including $PRXL's net debt. The transaction is expected to close early in 4Q17. $PRXL's BoD unanimously approved the transaction and plans to recommend that all $PRXL shareholders vote to approve the agreement,

$PRXL {{ '2017-06-15T12:58:57+0000' | timeago}} • Announcement

$PRXL announced a collaboration with Sanofi to advance the use of wearable devices to transform the collection of data in clinical trials. The $PRXL-Sanofi collaboration is designed to further explore the potential of patient sensors and wearable devices to remotely collect patient data during clinical trials.

$PRXL {{ '2017-02-28T15:27:23+0000' | timeago}} • Announcement

$PRXL appointed Simon Harford as Senior Vice President and Chief Financial Officer, effective June 1, 2017. In his new role, Harford will be based at the headquarters in Waltham, Massachusetts.

$PRXL {{ '2017-02-02T15:32:41+0000' | timeago}} • Announcement

$PRXL agreed to buy The Medical Affairs Co., a provider of outsourced medical affairs services to the pharmaceutical, biotechnology, and medical device industries, for undisclosed terms. The acquisition is expected to close in February.

$PRXL {{ '2016-11-22T18:11:04+0000' | timeago}} • Announcement

$PRXL entered into an accelerated share repurchase agreement (ASR) with HSBC Bank USA to purchase shares of its common stock for an aggregate purchase price of $200MM. $PRXL will receive about 2.8MM common shares. The shares will be repurchased at $57.51 per share.

$PRXL {{ '2016-09-26T13:47:11+0000' | timeago}} • Announcement

$PRXL agreed to buy ExecuPharm, a global functional service provider (FSP) serving the biopharmaceutical industry, for undisclosed terms. The acquisition is expected to close in the next three weeks.

$PRXL {{ '2016-09-19T14:50:47+0000' | timeago}} • Announcement

$PRXL appointed Christian Dreger as SVP, PAREXEL Access and PAREXEL Consulting. Dreger will also serve on PAREXEL's Business Review Committee, its senior-most leadership team, and assist in developing and implementing its strategic objectives.

$PRXL {{ '2016-08-01T13:32:15+0000' | timeago}} • Announcement

$PRXL said the company appointed four company executives to its Business Review Committee; David Godwin, as SVP, Global Business Development; Michelle Graham as SVP and Chief Human Resources Officer; Sy Pretorius as SVP and Chief Scientific Officer; and Joshua Schultz as SVP, Worldwide Head of PAREXEL Access.

$PRXL {{ '2016-06-30T15:24:28+0000' | timeago}} • Announcement

$PRXL said it reiterates its long-term financial goals, including: 10â??12% annual revenue growth, consisting of 7â??8% growth from ongoing operations and 3â??4% growth from acquisitions; 100â??120 points of adjusted operating margin improvement, with long-term goal range of 14â??16%; and 15â??20% annual adjusted diluted EPS growth.

$PRXL {{ '2016-06-30T15:23:00+0000' | timeago}} • Announcement

$PRXL said it expects FY17 GAAP EPS of $3.68-3.96, non-GAAP EPS of $3.75-4.03 and revenue of $2.175-2.205Bil. In recent years, $PRXL has seen strong growth in new business and backlog but also delay in converting backlog into revenue. $PRXL sees this trend to continue in FY17, when it sees revenue growth of 4â??5.5%.

$PRXL {{ '2016-06-30T15:19:03+0000' | timeago}} • Announcement

$PRXL said it lowered its 4Q16 GAAP EPS guidance to $0.79-0.87 from prior range of $0.87-0.95. $PRXL still sees 4Q16 non-GAAP EPS of $0.89-0.97 and revenue of $528-538MM. For FY16, $PRXL cut its GAAP EPS outlook to $2.85-2.93 from prior range of $2.93-3.01. $PRXL still sees FY16 non-GAAP EPS of $3.38-3.46 and revenue of $2.085-2.095Bil.

$PRXL {{ '2016-06-10T13:14:55+0000' | timeago}} • Announcement

Biopharmaceutical services provider $PRXL said it has signed a master services agreement with $PFE. Under the terms of this agreement, the company will continue to provide global clinical R&D services to $PFE in support of clinical development programs across its portfolio. Terms of the agreement were not disclosed.

$PRXL {{ '2016-01-21T16:17:19+0000' | timeago}} • Announcement

Optum, part of $UNH, and $PRXL said that they have entered into a strategic alliance to reduce drug development costs associated with post-approval studies. The deal combines the strength of Optum's clinical data set derived from electronic health records (EHRs), claims data assets and analytics with $PRXL's global, site-based research experience.

$PRXL {{ '2016-01-19T18:02:19+0000' | timeago}} • Announcement

Biopharmaceutical services company $PRXL said that it has agreed to acquire all outstanding equity securities of Health Advances, LLC, a life sciences consulting firm. The acquisition is expected to close in Feb., subject to closing conditions including expiration or termination of waiting period under the Hart-Scott-Rodino Act.

Recent Transcripts

IBM (International Business Machines Corporation)
Tuesday, October 17 2017 - 9:00pm
DYNT (Dynatronics Corp)
Wednesday, September 27 2017 - 12:30pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
XON (Intrexon Corporation)
Wednesday, August 9 2017 - 9:30pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
CRL (Charles River Laboratories International, Inc.)
Wednesday, August 9 2017 - 12:30pm
NAVB (Navidea Biopharmaceuticals, Inc)
Wednesday, August 9 2017 - 12:00pm
PRAH (PRA Health Sciences, Inc.)
Tuesday, August 8 2017 - 1:00pm
Q (Quintiles Transnational Holdings Inc.)
Thursday, August 3 2017 - 1:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
DNB (Dun & Bradstreet Corp.)
Thursday, August 3 2017 - 12:00pm
CTSH (Cognizant Technology Solutions Corporation)
Thursday, August 3 2017 - 12:00pm
EXEL (Exelixis, Inc.)
Wednesday, August 2 2017 - 9:00pm
SNMX (Senomyx Inc.)
Thursday, July 27 2017 - 9:00pm
CERN (Cerner Corporation)
Thursday, July 27 2017 - 8:30pm
UTHR (United Therapeutics Corporation)
Thursday, July 27 2017 - 1:00pm
ICLR (ICON Public Limited Company)
Thursday, July 27 2017 - 1:00pm
NLSN (Nielsen Holdings plc)
Thursday, July 27 2017 - 12:00pm
LH (Laboratory Corp. of America Holdings)
Wednesday, July 26 2017 - 1:00pm
EXAS (Exact Sciences Corporation)
Tuesday, July 25 2017 - 9:00pm

AlphaGraphics you may like